RARB and cancer: Transcriptomics and proteomics as a whole identified key DEPs of the THRB(−/−)/RL95-2 cells, including cellular junctions, metabolism, and cancer-related pathways, suggesting RARβ, CRABP2, and RXRA could be potential targets for MPA resistance and targeted by CANA.